Inclusion Criteria:  Age ≥60, male or female; patients with severe or above secondary tricuspid regurgitation (TR≥4+) (secondary tricuspid regurgitation: tricuspid regurgitation caused by right atrial lesions, right ventricular cardiomyopathy, right ventricular myocardial infarction, left ventricular valvular disease, congenital heart disease and other diseases); A multidisciplinary cardiac team (at least 2 doctors) consisting of cardiovascular physicians, cardiovascular surgeons, radiologists, anesthesiologists, etc., considered the subject to be at high risk for surgery and expected to benefit from tricuspid valve repair; Left ventricular ejection fraction LVEF≥40%; The subject voluntarily participates in the clinical trial and agrees or his/her guardian agrees to sign the informed consent. Tricuspid regurgitation symptoms, such as chest tightness, asthma, shortness of breath, lower limb edema, ascites; NYHA grade 2 to 4; Patients who received tricuspid valve optimal drug therapy for ≥ 30 days were in stable condition; In the case of the following diseases: mitral regurgitation, atrial fibrillation, coronary disease and heart failure, drug treatment should be ≥ 30 days or ≥ 30 days after instrumental treatment and the patient's condition is stable.  Exclusion Criteria:  patients with primary tricuspid regurgitation; Patients with systolic pulmonary artery pressure ≥55 mmHg; Patients with tricuspid valve or annuloplasty or tricuspid related procedure; Patients with posterior tricuspid annulus calcification; Evidence of mass, thrombosis or vegetations in the heart, jugular vein and superior vena cava; patients with moderate or higher aortic stenosis, mitral stenosis, aortic regurgitation or mitral regurgitation; patients with severely uncontrolled hypertension (systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg); Percutaneous coronary intervention within 1 month; myocardial infarction or known unstable angina within 1 month; Cerebrovascular accident within the past 3 months; patients with active endocarditis or active rheumatic heart disease; Patients with coagulation dysfunction, hypercoagulability or anemia (hemoglobin < 90 g/L); patients with acute infection or other severe infection; Patients with active peptic ulcer or active gastrointestinal bleeding; severe end-stage diseases (such as malignant tumor, severe lung disease, liver disease, renal failure) with a life expectancy of less than one year; Patients with known allergies or contraindications to the raw materials or drugs (such as antiplatelet drugs and anticoagulants) of the test products; Persons addicted to alcohol, drugs or drugs; Patients with cognitive impairment; patients with histories of epilepsy or mental illness; Participate in any other clinical trial (other than a registry study) within 30 days prior to signing the informed consent; have a previous implantation of a pacemaker or defibrillator, or plan to implant a pacemaker or defibrillator; Tricuspid stenosis; Ebstain syndrome; The anatomy of tricuspid annulus could not be assessed by TEE and TTE; Hemodynamic instability; Active endocarditis; Active rheumatic heart disease; chronic dialysis patients; women who are pregnant during pregnancy, breast-feeding or during the clinical study; Other conditions that the investigator considers inappropriate for participation in the clinical trial.